Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform

By LabMedica International staff writers
Posted on 29 Sep 2021

Illustration

Mammoth Biosciences (San Francisco, CA, USA) presented its revolutionary CRISPR-based detection platform that is enabling limitless testing possibilities and was also one of the AACC 2021 Disruptive Technology award finalists.

Mammoth has catalyzed a new approach to molecular diagnostics, called DETECTR. Based on CRISPR, this programmable platform acts as a search engine for biology and is capable of finding and identifying any nucleic acid sequence in the genome. Using proprietary technology licensed exclusively from the University of California, Berkeley and developed internally, Mammoth is working on multiple form factors and test targets from infectious diseases to cancer. For example, DETECTR was configured in less than two weeks to detect SARS-CoV-2, demonstrating the platform’s ability to be quickly tailored to identify any DNA or RNA target. The resulting product, DETECTR BOOST, is a reagent kit that when combined with standard laboratory automation provides labs with unparalleled high throughput molecular testing.

Mammoth was also one of the AACC 2021 Disruptive Technology award finalists. AACC's Disruptive Technology Award Competition recognizes innovative testing and disruptive technology solutions that improve patient care through diagnostic performance or access to high quality testing. It provides an opportunity for early to mid-stage start-ups in the medical device, diagnostic, or digital health/health IT spaces to showcase their technology and present to a large audience and a panel of judges.

Related Links:
Mammoth Biosciences

Visit expo >

Platinum Member

Automated Coagulation Analyzer

Hemolumi H6

Gold Member

Neonatal Heel Incision Device

Tenderfoot

Food Allergy Screening ELISA Kit

Allerquant 14G B ELISA

Automatic CLIA Analyzer

Shine i6000

Latest AACC 2021 News

Channels

Clinical Chemistry

view channel

Image: Findings show that low circulating ISM2 around 12 weeks gestation was the strongest indicator of later pregnancy complications (Image Credit: Adobe Stock)

New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction

Preeclampsia and fetal growth restriction are major drivers of stillbirth and serious maternal morbidity, yet clinicians still lack reliable early predictors to guide targeted surveillance.... Read more

Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction

Takotsubo syndrome, often called broken-heart syndrome, mimics myocardial infarction and can be difficult to triage in emergency settings. It accounts for about 2% of suspected heart attacks and up to... Read more

New Biomarker Recommendations Aim to Personalize Stroke Rehabilitation

Stroke affects more than 795,000 Americans each year, leaving many survivors with lasting motor, speech, and cognitive deficits. Because rehabilitation outcomes vary widely, clinicians still face challenges... Read more

NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis

Long COVID presents with heterogeneous, persistent symptoms that complicate clinical assessment and case definition. A lack of a definitive diagnostic test forces clinicians to exclude alternative etiologies... Read more

Molecular Diagnostics

view channel

Hematology

view channel

New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome

Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more

Ultra-Portable Device Enables Finger-Prick Blood Testing at Home

Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more

Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam

Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more

Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma

Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read more

Immunology

view channel

New Cellular Map May Help Predict Crohn’s Disease Course in Children

Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more

Temporal Immune Profiling Reveals How Sepsis States Change Over Time

Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more

Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19

Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read more

Gut “Memory” May Explain Why IBD Flares Return

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are characterized by recurring flare-ups that damage the intestinal mucosa and remain difficult to predict.... Read more

Microbiology

view channel

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more

Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs

Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more

Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.

Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more

Pathology

view channel

Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples

Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more

Image: Graphical Abstract (Vivek Behera et al., Pan-tumor spatial transcriptomics reveals conserved properties of tumor organization, Cell Reports Medicine, 2026. DOI: 10.1016/j.xcrm.2026.103013)

AI Tool Improves Prediction of Immunotherapy Response in Lung Cancer

Immune checkpoint therapies benefit only a subset of patients, while standard biomarkers often struggle to predict who will respond. Spatially resolved tumor profiling can provide deeper biological context,... Read more

New Journal Addresses Evolving Needs in Clinical and Translational Pathology

Clinical pathology underpins diagnosis and therapy selection across oncology and other major diseases, but the field is rapidly evolving as new technologies reshape how disease is studied and classified.... Read more

Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Technology

view channel

Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins

Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more

Autonomous Robotic System Receives FDA Authorization for Blood Collection

Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more

Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results

Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more

Training Device Improves Accuracy of Pooled Molecular Diagnostics

High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more

Industry

view channel

New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers

Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more

Fujirebio Expands Access to Automated Blood-Based Neurology Testing in Canada

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio announced that Health Canada has issued Class II Medical Device Licenses for Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma for... Read more

Natera ctDNA Test to Support Response Monitoring in Solid Tumor Trial

ANatera’s Signatera test will be used in a partnership with Angiex to evaluate patients receiving AGX101, a Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) in a Phase I clinical trial.... Read more

$Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)$

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more

See LabMedica in...

LabMedica

Mammoth Biosciences Presents AACC 2021 Disruptive Technology Award Finalist CRISPR-Based Detection Platform

Latest AACC 2021 News

Channels